[A21-22] Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V
Last updated 17.05.2021
Project no.:
A21-22
Commission:
Commission awarded on 12.02.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adult and adolescent patients aged 12 years and above with influenza exposure
Affected people without risk of influenza-related complications: indication of considerable added benefit.
Affected people with risk of influenza-related complications: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-21 | Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V | Commission completed |